A comprehensive analysis of cytokine profiles activated by IL-33 in various cancers may help clarify the CD4+ T cell subsets (including Treg) targeted by IL-33 in relation to the specific TME and anti-tumor response elicited. The gene discussed is IL33; the disease is neoplasm.